Recherche Fr menu fr ClientConnect
Recherche
Résultats
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
Référence: 20200634
Date de publication: 27 janvier 2021

Promoteur – Intermédiaire Financier

AB SCIENCE SA

Lieu

Description

The project finances the borrower's expenditures over the next three years related to Masitinib and its analogues against COVID-19 (non-clinical and clinical studies, drug manufacturing including stock piling, related regulatory expenses, related general and administrative (G&A) expenses).The project will be implemented from Paris, France.

Objectifs

The project finances the borrower's expenditures over the next three years related to Masitinib and its analogues against COVID-19 (non-clinical and clinical studies, drug manufacturing including stock piling, related regulatory expenses, related G&A expenses).The project will be implemented from Paris, France. The company's innovative approach might prevent complications linked to severe pulmonary inflammation and thrombotic events potentially leading to death. It also aims to reduce the burden on intensive care units and more invasive treatment options. By co-investing in the project, the Bank contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities.

Secteur(s)

  • Services - Activités spécialisées, scientifiques et techniques

Montant BEI envisagé (montant approximatif)

EUR 15 million

Coût total (montant approximatif)

EUR 35 million

Aspects environnementaux

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Passation des marchés

The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. Details will be assessed during the project's due diligence.

Statut

Signé - 27/11/2020

Clause de non-responsabilité

Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).

Mots-clés correspondants

France Services